David A. Siegel Galmed Pharmaceuticals Ltd. Transaction History

Two Sigma Advisers, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$2.41 - $3.33 $36,632 - $50,616	-15,200 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$2.24 - $3.9 $5,152 - $8,970	-2,300 Reduced 13.14%	15,200 $46,000
Q1 2021 May 17, 2021	BUY	$3.19 - $5.4 $55,825 - $94,500	17,500 New	17,500 $60,000

Ticker GLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,088,400
Market Cap $78.3M
Description
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or t...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.